DK1648882T3 - 3-fluor-piperidiner som NMDA/NR2B-antagonister - Google Patents

3-fluor-piperidiner som NMDA/NR2B-antagonister

Info

Publication number
DK1648882T3
DK1648882T3 DK04753896T DK04753896T DK1648882T3 DK 1648882 T3 DK1648882 T3 DK 1648882T3 DK 04753896 T DK04753896 T DK 04753896T DK 04753896 T DK04753896 T DK 04753896T DK 1648882 T3 DK1648882 T3 DK 1648882T3
Authority
DK
Denmark
Prior art keywords
nmda
piperidines
fluoro
nr2b antagonists
nr2b
Prior art date
Application number
DK04753896T
Other languages
Danish (da)
English (en)
Inventor
Nigel J Liverton
Christopher F Claiborne
David A Claremon
John A Mccauley
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33511734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1648882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK1648882T3 publication Critical patent/DK1648882T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
DK04753896T 2003-06-04 2004-05-28 3-fluor-piperidiner som NMDA/NR2B-antagonister DK1648882T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47593803P 2003-06-04 2003-06-04
PCT/US2004/017175 WO2004108705A1 (en) 2003-06-04 2004-05-28 3-fluoro-piperidines as nmda/nr2b antagonists

Publications (1)

Publication Number Publication Date
DK1648882T3 true DK1648882T3 (da) 2008-11-24

Family

ID=33511734

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04753896T DK1648882T3 (da) 2003-06-04 2004-05-28 3-fluor-piperidiner som NMDA/NR2B-antagonister

Country Status (30)

Country Link
EP (1) EP1648882B1 (no)
JP (1) JP3927228B2 (no)
KR (1) KR20060017839A (no)
CN (1) CN1798744A (no)
AR (1) AR044579A1 (no)
AT (1) ATE403651T1 (no)
AU (1) AU2004245522B2 (no)
BR (1) BRPI0410837A (no)
CA (1) CA2527093C (no)
CL (1) CL2004001365A1 (no)
CO (1) CO5700762A2 (no)
DE (1) DE602004015610D1 (no)
DK (1) DK1648882T3 (no)
EC (1) ECSP056192A (no)
ES (1) ES2309540T3 (no)
HR (1) HRP20080490T3 (no)
IS (1) IS8117A (no)
MA (1) MA27781A1 (no)
MX (1) MXPA05013151A (no)
MY (1) MY138547A (no)
NO (1) NO20060020L (no)
PE (1) PE20050245A1 (no)
PL (1) PL1648882T3 (no)
PT (1) PT1648882E (no)
RU (1) RU2339630C2 (no)
SI (1) SI1648882T1 (no)
TW (1) TW200510378A (no)
UA (1) UA81319C2 (no)
WO (1) WO2004108705A1 (no)
ZA (1) ZA200509000B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007247851A1 (en) * 2006-05-03 2007-11-15 Relevare Aust. Pty Ltd Methods and composition for treatment of inflammatory pain
MX2009011416A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
EP2175886A1 (en) * 2007-06-28 2010-04-21 CNSBio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
EP2536713A1 (en) 2010-02-16 2012-12-26 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
JP6042968B2 (ja) 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
CN103936663B (zh) * 2013-01-23 2016-12-28 艾琪康医药科技（上海）有限公司 一种1-r1-3,3-二氟(或3-氟)-4-r2-4-氨甲基哌啶及其衍生物的制备方法
US9187506B2 (en) 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US9221796B2 (en) 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
CN106795163B (zh) 2014-06-04 2019-07-30 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的二氟乙基吡啶衍生物
ES2723436T3 (es) 2014-09-15 2019-08-27 Rugen Holdings Cayman Ltd Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B
US20180271869A1 (en) * 2014-09-22 2018-09-27 Jie Liu Treatment of anxiety disorders and autism spectrum disorders
JP2018506514A (ja) * 2014-12-23 2018-03-08 セレコー，インコーポレイテッド 化合物、組成物および方法
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
EP3303323B1 (en) 2015-06-01 2020-01-08 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
AU2016340237A1 (en) 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists
KR20180064507A (ko) 2015-10-14 2018-06-14 브리스톨-마이어스 스큅 컴퍼니 선택적 nr2b 길항제
JP6916799B2 (ja) 2016-08-31 2021-08-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
EP3544610A1 (en) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379520B2 (en) * 2001-02-23 2014-04-09 Merck Sharp & Dohme Corp. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Also Published As

Publication number Publication date
ZA200509000B (en) 2006-12-27
ES2309540T3 (es) 2008-12-16
CA2527093C (en) 2009-10-20
JP2006526650A (ja) 2006-11-24
TW200510378A (en) 2005-03-16
NO20060020L (no) 2006-03-03
ECSP056192A (es) 2006-04-19
EP1648882A1 (en) 2006-04-26
UA81319C2 (en) 2007-12-25
SI1648882T1 (sl) 2009-02-28
MA27781A1 (fr) 2006-02-01
RU2339630C2 (ru) 2008-11-27
EP1648882B1 (en) 2008-08-06
IS8117A (is) 2005-11-07
AR044579A1 (es) 2005-09-21
JP3927228B2 (ja) 2007-06-06
PE20050245A1 (es) 2005-04-13
HRP20080490T3 (en) 2008-11-30
CA2527093A1 (en) 2004-12-16
WO2004108705A1 (en) 2004-12-16
MY138547A (en) 2009-06-30
MXPA05013151A (es) 2006-03-17
BRPI0410837A (pt) 2006-06-27
CL2004001365A1 (es) 2005-05-06
KR20060017839A (ko) 2006-02-27
CO5700762A2 (es) 2006-11-30
ATE403651T1 (de) 2008-08-15
PL1648882T3 (pl) 2008-12-31
AU2004245522A1 (en) 2004-12-16
PT1648882E (pt) 2008-10-20
CN1798744A (zh) 2006-07-05
DE602004015610D1 (de) 2008-09-18
RU2005137704A (ru) 2006-05-27
AU2004245522B2 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
IS8117A (is) 3-Flúr-píperidín sem NMDA/NR2B mótlyf
NO20052739D0 (no) CCR5-antagonister som medikamenter
ATE481402T1 (de) Pyrazolopyridin-derivate
AT500118A3 (de) Mehrfach-funkgerät-vereinheitlichungsprotokoll
DK3494995T3 (da) Superfin formoterolformulering
NO20054669D0 (no) Substituerte kinobenzoxazinanaloger
DE602004022685D1 (de) Abgabevorrichtung
DE602004025473D1 (de) Mehrkomponentiges spinnvlies
DE602004004278D1 (de) 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
DE60335075D1 (de) Flüssigkeitszerstäuber
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
IS7991A (is) Setnar p-díamínóbensen afleiður
DK1406888T3 (da) Substituerede gamma-lactonforbindelser som NMDA-antagonister
DE602004027577D1 (de) Hubschrauber
DE502004001392D1 (de) Sprühanordnung
ATE365529T1 (de) Schweisshemmende zusammensetzungen
DE502004001803D1 (de) Faltschachtel
DE112004000410D2 (de) Sprühvorrichtung
ATA8202003A (de) Hochspannungsmast
DE502004004196D1 (de) Ultraschall-stehwellen-zerstäuberanordnung
BR0317312B1 (pt) adaptador.
FR2852619B1 (fr) Echafaudage volant
DE502004006442D1 (de) Bauelement
FI20030283A (fi) Sovitinlaite